Measurement of involved surface area in patients with psoriasis

Ramsay, B.; Lawrence, C.M.

doi:10.1111/j.1365-2133.1991.tb04952.x

Cited by 169 publications

(149 citation statements)

References 6 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Intra-rater reliability for the BSA has also previously been described as very good. 14,15 Two studies conducted by Berth-Jones et al have demonstrated substantial intra-rater reliability for the PASI and PGA, and higher reproducibility for the PASI than for the PGA. 8,12 However, the data presented by Langley and Ellis revealed over 12 times higher intrarater variation for the PASI than for the PGA.…”

Section: Discussionmentioning

confidence: 99%

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Bożek¹,

Reich²

2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Bożek¹,

Reich²

2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…The rule of 9's, a method of estimating surface area based on attributing a given percentage to each body part, is used to estimate involved body surface area, e.g. in psoriasis (Ramsay, et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

“…Other scores like Psoriasis Area and Severity Index (PASI) or SCORAD (SCORing Atopic Dermatitis) depend heavily on assessment of the skin area, but this assessment has repeatedly been shown to be hard to reproduce (Charman, et al, 2000;Tiling-Grosse, et al, 1993;Charman, et al, 1999). Because CLE, like guttate psoriasis, involves only small proportions of the skin, area assessment is even more difficult than in atopic dermatitis or plaque psoriasis (Ramsay, et al, 1991). Lesion counting, commonly used for acne, is not a suitable alternative, because the reliability of the lesion counting is not necessarily better (Lucky, et al, 1996) and the lesions of CLE have widely varying size and may be confluent.…”

Section: Areamentioning

confidence: 99%

The CLASI (Cutaneous LE Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus

2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

We developed and validated a measurement instrument (CLASI -Cutaneous Lupus Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate scores for damage and activity. A group of 7 American Dermato-Rheumatologists and the "American College of Rheumatology Response Criteria Committee on SLE" assessed content validity. After a preliminary session, we conducted standardized interviews with the raters and made slight changes to the instrument. The final instrument was evaluated by 5 dermatologists and 6 residents who scored 9 patients to estimate inter-rater reliability and intra-rater reliability in two sessions. Consultation with experts has established content validity of the instrument. Reliability studies demonstrated an Intraclass Correlation Coefficient (ICC) for inter-rater reliability of 0.86 for the activity score (95% Confidence Interval [CI] 0.73 to 0.99) and of 0.92 for the damage score (95% CI 0.85 to 1.00). The Spearman's Rho for intra-rater reliability for the activity score was 0.96 (95% CI 0.89 to 1.00) and for the damage score Spearman's Rho was 0.99 (95% CI 0.97 to 1.00). Clinical responsiveness needs to be evaluated in a prospective clinical trial, which is ongoing. KeywordsCutaneous Lupus Erythematosus; Discoid Lupus Erythematosus; Subacute Lupus Erythematosus; Clinical Trial; Outcome Instrument IntroductionCharacteristic inflammatory skin changes are seen in a large majority of individuals with systemic lupus erythematosus (SLE). However, the cutaneous manifestations of lupus erythematosus (LE) are among the least systematically studied aspects of these autoimmune Corresponding author: Victoria Werth, MD, Professor of Dermatology and Medicine, Department of Dermatology, 2, Rhodes Pavillion, 3600 Spruce Street, Philadelphia, PA 19119, Tel.: 215-823-4439, Fax.: 215-823-5994, werth@mail.med.upenn illnesses. This has resulted in part from the lack of validated tools to determine the impact of therapy on the activity of the cutaneous manifestations of LE. Disease activity measurements for skin diseaseDuring the last three decades there have been numerous attempts to develop instruments to measure skin disease. As a good approximation of the available scores, the Medical Algorithm Project lists 108 medical algorithms in dermatology [www.medal.com, accessed 09/15/2004], the majority of which are scores to assess clinical disease. Unfortunately, most of the developed scores are disease-specific. There are some general scores, like the Dermatology Index of Disease Severity (DIDS) (Faust, et al., 1997), but they are too crude in their assessment of body surface area to be useful for diseases like acne or cutaneous lupus erythematosus (CLE), which only affect relatively small areas of the skin (Williams, 1997).In a recent retrospective study, Parodi et al. noted that 60 measures of systemic lupus erythematosus were available, but only three of these appeared useful for dermatologists (Parodi, et al., 2000). Based on t...

show abstract

“…Score <4 was considered as remission, in the range of >4 -<14 low disease activity, >14 -<28 moderate disease activity; whereas > 28 reflect high disease activity. Skin affection was assessed using both they included Body Surface Area (BSA) [18], and Psoriasis Area and Severity Index (PASI) [19]. PASI score <1 was considered in remission, score < 10 was considered as mild, 10-20 moderate whereas PASI score > 20 was considered as severe.…”

Section: Data Collectionmentioning

confidence: 99%

Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients

Miedany¹,

Gaafary²,

Youssef³

et al. 2017

Rheumatol Orthop Med

View full text Add to dashboard Cite

Objective: 1. identify comorbidities with greatest impact on PsA patients' health status. 2.develop and validate a prospectively applicable comorbidity index for classifying PsA patients according to their comorbid conditions. Methods:This was a retrospective multicenter cohort analysis of PsA patients in a rheumatology clinical registry, assessing the effect of different comorbidities measured at patients' visits over 10-years period. Outcomes of interest included functional ability, quality of life, medications induced complications, hospitalization/ death. A weighted index that was developed in a cohort of 1707 PsA patients. Internal and external validation were carried out.Results: PsA patients who had higher incidence of comorbid condition and were at high risk of hospitalization were men, with older age at disease onset, high BMI (p < 0.05). Multivariate regression analysis identified 29 comorbidities. A comorbidity index weighted according to the regression coefficient of the variables was developed (the score range: 0-37). A cut off point of 8 was associated with a sensitivity of 97.5% and a specificity of 87%. The developed PsACI correlated significantly with the 4 tested comorbidity indices: Charlson comorbidity index, Functional comorbidity index, Rheumatic Diseases comorbidity index, and Multimorbidity index at 1-, 3-, 5-and 10-years. Similar significant correlation was seen on external validation assessment. Conclusion:The PsA-comorbidity index is a valid method for estimating comorbidity risk in PsA patients. It enables the clinicians to include comorbidities assessment and management in their practice. It can be used to predict resource utilization, identify targets for reducing costs, by prospectively identifying PsA patients at high risk.

show abstract

Measurement of involved surface area in patients with psoriasis

Cited by 169 publications

References 6 publications

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

The CLASI (Cutaneous LE Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus

Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients

Contact Info

Product

Resources

About